Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.56 |
| ▸ | PGR | P06401 | 7/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23547250 | 1.00 | NR3C1 (0.56) | NR3C1PGRNR3C2ARKDM1A | |
| SCHEMBL23525739 | 1.00 | NR3C1 (0.56) | NR3C1PGRNR3C2ARKDM1A | |
| SCHEMBL23547261 | 0.81 | NR3C1 (0.53) | NR3C1PGRNR3C2ARKDM1A | |
| SCHEMBL23525700 | 0.81 | NR3C1 (0.53) | NR3C1PGRNR3C2ARKDM1A | |
| SCHEMBL23547249 | 0.81 | NR3C1 (0.53) | NR3C1PGRNR3C2ARKDM1A | |
| SCHEMBL7091504 | 0.72 | NR3C1 (0.48) | NR3C1PGRNR3C2ARKDM1A | |
| SCHEMBL30023958 | 0.69 | PTGS1 (0.57) | NR3C1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12811024 | 0.69 | PTGS1 (0.57) | NR3C1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12017964 | 0.67 | SMN1; SMN2 (0.67) | KDM1AALDH1A1SMN1; SMN2CYP17A1 | |
| SCHEMBL23525734 | 0.67 | NR3C1 (0.53) | NR3C1PGRNR3C2ARKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188775-A1 | CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS | GENENTECH, INC. (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188775-A1 | CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS | TEAD2, TEAD1, SULT2A1 | NR3C1 4525/4885PGR 4346/4885NR3C2 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.